
FDA Removes PCNSL Limitation From Liso-Cel Label
Key Takeaways
- Labeling for liso-cel now permits use in LBCL even with concomitant PCNSL/secondary CNSL, reversing prior exclusion while keeping the indication framed under LBCL rather than PCNSL.
- Study 6 PCNSL cohort showed CRS in 60% without grade ≥3 events, whereas neurologic toxicities occurred in 40% with onset 3–8 days and duration 7–22 days.
The November 2026 prescribing information removes the limitation that previously excluded patients with primary or secondary central nervous system lymphoma from the therapy’s large B-cell lymphoma indications.
The FDA has removed the limitation of use excluding patients with primary or secondary central nervous system lymphoma (CNSL) from the large B-cell lymphoma (LBCL) indications for lisocabtagene maraleucel (Breyanzi; liso-cel).The update removes the previous restriction on use in patients with primary central nervous system lymphoma (PCNSL) and adds safety information from a small cohort of patients with relapsed or refractory PCNSL.1
Liso-cel is a
The label revision removes the prior limitation stating that liso-cel is not indicated for patients with PCNSL. It does not establish a separate indication specifically for PCNSL.
The update also makes liso-cel the second CAR T-cell therapy to have this limitation removed, following axicabtagene ciloleucel (Yescarta; axi-cel), whose
PCNSL-Specific Safety Findings With Liso-Cel
The November 2026 prescribing information includes safety findings from Study 6 (JCAR017-BCM-001), a single-arm, multicenter study that evaluated liso-cel in 5 patients with relapsed or refractory PCNSL.
Cytokine release syndrome (CRS) occurred in 60% of patients in this cohort, with no grade 3 or higher events reported. Neurologic toxicities occurred in 40% of patients (n = 2/5), with events including seizure, headache, encephalopathy, and paresis. Each of these neurologic events was reported in 20% of patients. The reported onset of neurologic toxicities ranged from 3 to 8 days, and their duration ranged from 7 to 22 days.
Other adverse events reported in the 5-patient cohort included fever (40%), unspecified infection (20%), musculoskeletal pain (20%), cough (20%), hemorrhage (20%), and hypertension (20%). The unspecified infection and hemorrhage events were reported as grade 3 or higher.
The prescribing information also reports that, across clinical trials of liso-cel excluding the PCNSL cohort, neurologic toxicities including immune effector cell-associated neurotoxicity syndrome (ICANS) occurred in 32% of patients, including grade 3 or higher events in 10%. These broader safety findings should be distinguished from the results in the dedicated PCNSL cohort.
Updated Label Follows Earlier CAR T-Cell Revision
The February 2026 label update for axi-cel also removed the limitation of use for patients with PCNSL. That revision followed a phase 1 safety study that included 13 patients with relapsed or refractory PCNSL and 5 patients with secondary CNS lymphoma.2
The updated labeling for liso-cel similarly incorporates safety information from patients with PCNSL, while removing the previous restriction from its LBCL indications.
Liso-cel continues to carry boxed warnings for CRS, ICANS, and secondary hematologic malignancies. The prescribing information recommends monitoring patients for these potentially serious complications following treatment.
REFERENCES
Breyanzi (lisocabtagene maraleucel). Prescribing information. Bristol Myers Squibb; November 2026. Accessed November 18, 2026. https://packageinserts.bms.com/pi/pi_breyanzi.pdf
FDA approves label update for Kite’s Yescarta for relapsed/refractory primary central nervous system lymphoma. News release. Kite Pharma. February 6, 2026. Accessed November 18, 2026. https://tinyurl.com/3cwu6jvm
Related to this article







